EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera

Albert Qin iD, Daoxiang Wu, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Jason Liao, Sheena Lin, Cynthia Chang, Haoqi Chen, Jie Cui, Xia Su

British Journal of Clinical Pharmacology · 2024-06 · 90 (6) · 1493-1502

DOI: 10.1111/bcp.16043 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.03.2024. Verfasst von Albert Qin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan, ROC. Hauptthemen laut MEDLINE: Recombinant Proteins, Interferon-alpha, Polyethylene Glycols, Interferon alpha-2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: PharmaEssentia Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the exposure–response (E‐R) relationship, including exposure–efficacy and exposure–safety, of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera (PV).

Methods

Based on the results of the phase II trial A20‐202 regarding ropeginterferon alfa‐2b in patients with PV, E‐R analyses were performed to evaluate the efficacy and safety of the given dosing regimen. The E‐R analyses were based on logistic and linear regression and the relationship between exposure to ropeginterferon alfa‐2b and key efficacy and safety variables. The key efficacy variables included complete haematologic response (CHR) and reduction of the driver mutation JAK2 V617F. The safety variable was treatment‐related adverse events (TRAEs).

Results

A clear relationship between the exposure to ropeginterferon alfa‐2b and CHR was observed, with an increase in drug exposure resulting in an increased probability of achieving CHR. Similar CHR probabilities were observed in the third and fourth quantiles of the average concentration at Week 24. The results from the exposure– JAK2 V617F model indicated that the JAK2 V617F allele burden decreased with increasing exposure to ropeginterferon alfa‐2b and baseline body surface area. Exposure–safety analysis revealed a risk of AEs associated with transaminase abnormalities, which were not associated with clinical significance.

Conclusions

Our analyses have shown that patients with PV treated with ropeginterferon alfa‐2b had an increased probability of achieving CHR and a molecular response with acceptable safety risks at the 250–350–500 μg titration dosing regimen. This study has provided the relevant data for the application of a biologics licence of ropeginterferon alfa‐2b for PV treatment in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant ProteinsInterferon-alphaPolyethylene GlycolsInterferon alpha-2Polycythemia VeraJanus Kinase 2HumansMaleFemaleMiddle AgedTreatment OutcomeDose-Response Relationship, DrugAgedAdult

Stichwörter der Autor:innen

Emax modelJAK2V617F allele burdencomplete haematologic responseexposure–efficacy and exposure–safety analysespolycythaemia veraropeginterferon alfa‐2b

Substanzen

Recombinant ProteinsInterferon-alphaPolyethylene GlycolsInterferon alpha-2peginterferon alfa-2bJanus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan, ROC.
  • PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Pharmaron Clinical Services Co., Ltd, Chengdu, China.

ORCID-Profile: Albert Qin

Förderung

  • PharmaEssentia Corporation

Zitieren

APA

Qin, A., Wu, D., Li, Y., Zhang, J., Wang, W., Shen, W., Liao, J., Lin, S., Chang, C., Chen, H., Cui, J., & Su, X. (2024). Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera. British Journal of Clinical Pharmacology, 90(6), 1493-1502. https://doi.org/10.1111/bcp.16043

Vancouver

Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, et al. Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera. British Journal of Clinical Pharmacology. 2024;90(6):1493-1502. doi:10.1111/bcp.16043

BibTeX
@article{Qin2024,
  author = {Qin, Albert and Wu, Daoxiang and Li, Yaning and Zhang, Jingjing and Wang, Wei and Shen, Weihong and Liao, Jason and Lin, Sheena and Chang, Cynthia and Chen, Haoqi and Cui, Jie and Su, Xia},
  title = {Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  volume = {90},
  number = {6},
  pages = {1493--1502},
  doi = {10.1111/bcp.16043}
}
Kostenlos starten →